Epizyme (EPZM) Updates on Clinical Programs; Tazemetostat Granted FDA Fast Track Designation in DLBCL
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Stocks end near flat as investors assess earnings, data
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Epizyme Announces Fast Track Designation for Tazemetostat in DLBCL and Provides Solid Tumor Program Update
November 28, 2016 6:30 AM ESTFDA Grants Tazemetostat Fast Track Designation for DLBCL with EZH2 Activating Mutations
Company Focuses Phase 2 Solid Tumor Study on INI1-Negative Tumors and Expands Epithelioid Sarcoma Cohort
CAMBRIDGE, Mass., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced advancements in the Companys clinical programs evaluating tazemetostat, its first-in-class EZH2 inhibitor. The U.S.... More
